Improvements in Bladder Diary Variables

Slides:

Advertisements

Similar presentations

TO PEE OR NOT TO PEE THAT IS THE QUESTION

Advertisements

NICE LUTS Clinical Guideline 2010

Urinary Incontinence Dr. Nedaa Bahkali 2012.

New drugs and the management of incontinence Stephen Mark.

Revolution in Asian drug development: A Korea and Japan experience Henk de Koning Gans, MD VP, Process Management Global Development Japan Pharmacia KK,

Botox® for the overactive bladder -The evidence Philip Toozs-Hobson Consultant Urogynaecologist.

Index Values NATIONAL STATISTICAL COORDINATION BOARD.

Statistical Analysis of the Regression Point Displacement Design (RPD)

SOME STATISTICAL CONCEPTS Chapter 3 Distributions of Data Probability Distribution –Expected Rate of Return –Variance of Returns –Standard Deviation –Covariance.

OnabotulinumtoxinA (Botox®) for the Treatment of Overactive Bladder

Urinary Incontinence Victoria Cook

Nursing approaches for urgency and Urge Incontinence

LUTS Shawket Alkhayal Consultant Urological Surgeon Benenden Hospital Tunbridge Wells Nuffield Hospital.

Urology Update Sanofi- Aventis

Overactive Bladder and Urge Incontinence in Men: Current Opinions, Medical, and Surgical Management 臺大泌尿部姜宜妮醫師.

Study day clinical cases nd Seminar Clinical cases in urodynamics. One morning with Paul Abrams presented by: Dr. Jose Emilio Batista Centro Médico.

 decimals/cc-7th-fracs-to-decimals/v/converting-fractions-to-decimals-example.

Urinary Incontinence (UI) Management in Family Practice References: Can Fam Physician 2003;49: Can Fam Physician 2003;49: SOGC Clinical.

Keeping the right patients away from hospital

How to use a covariate to get a more sensitive analysis.

Over active bladder drug treatment Mark Weatherall University of Otago Wellington.

ECONOMIC EVALUATION OF THE USE OF OXYBUTYNIN, TOLTERODINE AND SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER February 6, 2009.

Update On OAB Joon Chul Kim The Catholic University of Korea.

PROF. Rosita Aniuliene LITHUANIAN UNIVERSITY OF HEALTH SCIENCES President of Lithuanian Association of Urogynecology.

WEEK 1 You have 10 seconds to name…

Study day clinical cases nd Seminar Clinical cases in urodynamics. One morning with Paul Abrams Presented by: Dr. Jose Emilio Batista Urodynamics.

Prescribing information is available at this meeting MODULE 3 TREATMENT OPTIONS AND EXPECTATIONS 1 DET 808.

Interna tional Neurourology Journal 2015;19: Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can.

Benign Prostatic Hyperplasia Rajan Narula Senior Staff Specialist The Townsville Hospital.

OAB / LUTS Urology Pathway for Primary Care within Frimley Health locality Developed with key local stakeholders including Urologists, Gynaecologists,

Urinary incontinence (UI) Niazy B Hussam Aldin PhD Clinical Pharmacy

Urinary Incontinence A Practical Approach.

Volume 50, Issue 3, Pages (September 2006)

International Neurourology Journal 2015;19:

Usefulness of sacral nerve modulation in a series of multiple sclerosis patients with bladder dysfunction Elena Andretta, Claudio Simeone, Edoardo Ostardo,

Efficacy of holmium laser enucleation of the prostate (HoLEP) in men with bladder outlet obstruction (BOO) and non-neurogenic bladder dysfunction Jong.

Algorithms of Incontinence Management Men

Volume 77, Issue 1, Pages (January 2011)

Current Management of OAB

International Neurourology Journal 2010;14:93-99

International Neurourology Journal 2011;15:

1Bristol Urological Institute 2Astellas Pharma Europe B.V.

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Common urological problems

Management of Male OAB; Current Status in Japan

Jean-Jacques Wyndaele European Urology Supplements

Bladder dysfunction in ALD and AMN

How to use a covariate to get a more sensitive analysis

Volume 45, Issue 4, Pages (April 2004)

Volume 56, Issue 1, Pages (July 2009)

6.11 The Urinary System The Urinary System

Volume 63, Issue 1, Pages (January 2013)

Evaluation and Medical Management of Benign Prostatic Hyperplasia

Volume 56, Issue 3, Pages (September 2009)

Volume 56, Issue 1, Pages (July 2009)

Volume 70, Issue 1, Pages (July 2016)

6.11 The Urinary System The Urinary System

Volume 54, Issue 4, Pages (October 2008)

Volume 70, Issue 1, Pages (July 2016)

Philip Toozs-Hobson, Pallavi Latthe European Urology Supplements

Volume 74, Issue 4, Pages (October 2018)

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

SMOKERS NONSMOKERS Sample 1, size n1 Sample 2, size n2

Disposition of Patients in the Atherogenic Dyslipidemia Study

Difference between the groups

Parkinson’s Disease and YOU-rination

DKO animals exhibit abnormal voiding pattern.

Fig. 2. Change in IPSS scores as a measure of treatment effectiveness

How to use a covariate to get a more sensitive analysis

Osteoarthritis and Cartilage

Presentation transcript:

Improvements in Bladder Diary Variables Urgency episodes per 24 h Severe Urgency episodes per 24 h Micturitions per 24 h * † ‡ Statistical analysis for treatment differences using analysis of covariance. *P<0.05; †P<0.01; ‡P<0.001. PBO + α-blocker, 17%; TER+ α-blocker, 14% Adapted from Herschorn S. AUA 2008.

Improvements in IPSS * Total index Storage subscale Voiding subscale Statistical analysis for treatment differences using analysis of covariance. *P<0.0370. Adapted from Herschorn S. AUA 2008.

Change in Post-void Residual Urine Parameter Tolterodine ER (n=35) Solifenacin (n=36) Darifenacin (n=36) Mean at baseline 32.7 36.5 31.5 Mean at week 12 36.2 39.8 48.7 Mean change to week 12 3.5 3.3 17.2* Percentage change to week 12 10.7 9.0 54.6* *Two-sided P value for paired t test on change from baseline. Adapted from Kaplan SA. AUA 2008.